Acadian Asset Management’s Mereo BioPharma MREO Stock Holding History

Acadian Asset Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$68K	Buy	209,084 +147,649	+240%	+$63.4K	﹤0.01%	1814
2025 Q4	$24K	Sell	61,435 -194,943	-76%	-$371K	﹤0.01%	1896
2025 Q3	$522K	Buy	+256,378	New	+$473K	﹤0.01%	1203
2024 Q1	–	Sell	-62,843	Closed	-$144K	–	1706
2023 Q4	$144K	Buy	+62,843	New	+$120K	﹤0.01%	1293
2023 Q2	–	Sell	-191,899	Closed	-$134K	–	1843
2023 Q1	$134K	Buy	+191,899	New	+$173K	﹤0.01%	1337
2019 Q3	–	Sell	-1,302	Closed	-$3K	–	1960
2019 Q2	$3K	Buy	+1,302	New	+$5.69K	﹤0.01%	1704

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Acadian Asset Management's MREO Position: Q1 2026 in Review

Acadian Asset Management increased its Mereo BioPharma (MREO) stake by 240% in Q1 2026, buying an estimated $63.4K and bringing the position to 209,084 shares worth $68K. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

Acadian Asset Management first reported a position in MREO in Q2 2019 and has held it in 6 quarters since. The position peaked at $522K in Q3 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

Acadian Asset Management held 209,084 shares of Mereo BioPharma worth $68K as of Q1 2026.
Acadian Asset Management bought 147,649 Mereo BioPharma shares in Q1 2026, an estimated $63.4K.
Mereo BioPharma made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1814 holding.
Acadian Asset Management first reported a position in Mereo BioPharma in Q2 2019 and has held it in 6 quarters since.
Acadian Asset Management's Mereo BioPharma position peaked at $522K in Q3 2025.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.